Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to $3.2 million.

  • Fate Therapeutics' Depreciation & Amortization (CF) fell 2995.44% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 million, marking a year-over-year decrease of 2290.05%. This contributed to the annual value of $19.0 million for FY2024, which is 382.51% up from last year.
  • Per Fate Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $3.2 million for Q3 2025, which was down 2995.44% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Fate Therapeutics' Depreciation & Amortization (CF) registered a high of $4.9 million during Q4 2023, and its lowest value of $959000.0 during Q1 2021.
  • In the last 5 years, Fate Therapeutics' Depreciation & Amortization (CF) had a median value of $3.3 million in 2025 and averaged $3.5 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 18790.41% in 2022, then plummeted by 3086.5% in 2025.
  • Fate Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $2.3 million in 2021, then surged by 116.49% to $4.9 million in 2022, then grew by 0.39% to $4.9 million in 2023, then fell by 1.06% to $4.9 million in 2024, then tumbled by 33.48% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $3.3 million for Q2 2025, and $3.3 million during Q1 2025.